Your browser doesn't support javascript.
loading
Polypeptide P110 enhances the growth-inhibitory effect of cisplatin on colon cancer HCT-116 cells and xenotransplanted tumors in mice / 中华肿瘤杂志
Chinese Journal of Oncology ; (12): 816-820, 2012.
Article in Chinese | WPRIM | ID: wpr-307287
ABSTRACT
<p><b>OBJECTIVE</b>To observe the growth-inhibitory effect of polypeptide P110, designed with G3BP protein targets, plus cisplatin on human colon cancer HCT-116 cells and mouse colon cancer C26 xenotransplanted tumors in mice.</p><p><b>METHODS</b>The proliferation inhibition of HCT-116 cells and HUVEC cells in vitro was evaluated by MTT assay. A mouse model of xenotransplanted C26 mouse colon cancer was established. The inhibitory effects of P110 and cisplatin at different concentrations on C26 xenotransplanted tumors were assessed.</p><p><b>RESULTS</b>P110 enhanced the inhibitory effect of cisplatin on proliferation of HCT-116 cells. By treated with 20 µmol/LP110 + 10, 30, 90 µmol/L cisplatin, the proliferation inhibitory rates were (43.3 ± 3.2)%, (46.4 ± 4.6)% and (47.6 ± 5.8)%, respectively, significantly higher than that in the cisplatin group (P < 0.05). 20 µmol/L P110 + 10 µmol/L cisplatin effectively killed HCT-116 cells, whereas with less toxicity to HUVEC cells. The tumor inhibition rates in mice of P110 (25 mg/kg, 50 mg/kg, 100 mg/kg) plus cisplatin (1 mg/kg) were 23.0%, 30.4% and 34.2%, respectively. While, the tumor inhibition rates in mice of the cisplatin group (1 mg/kg) was 22.7%. Compared with cisplatin at the same concentration, the tumor inhibition rates in mice of the P110 plus cisplatin groups were all increased.</p><p><b>CONCLUSIONS</b>P110 can enhance the growth inhibitory effects of cisplatin on HCT-116 cells and C26 xenotransplanted tumors in mice. P110 plus cisplatin can reduce the effective dose of cisplatin and decrease the toxicity of cisplatin.</p>
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Pathology / Peptides / Pharmacology / Random Allocation / Cisplatin / Colonic Neoplasms / Xenograft Model Antitumor Assays / Cell Line, Tumor / HCT116 Cells / Tumor Burden Type of study: Controlled clinical trial Limits: Animals / Humans / Male Language: Chinese Journal: Chinese Journal of Oncology Year: 2012 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Pathology / Peptides / Pharmacology / Random Allocation / Cisplatin / Colonic Neoplasms / Xenograft Model Antitumor Assays / Cell Line, Tumor / HCT116 Cells / Tumor Burden Type of study: Controlled clinical trial Limits: Animals / Humans / Male Language: Chinese Journal: Chinese Journal of Oncology Year: 2012 Type: Article